Clinical Trials Browser

OTHER × Triple Negative Breast Neoplasms × Bexarotene × Clear all

NCT04664829 2025-09-23

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

Phase 1 Completed

Triple Negative Breast Neoplasms